Literature DB >> 406803

The menace of mass screening.

A B Bergman.   

Abstract

Mesh:

Year:  1977        PMID: 406803      PMCID: PMC1653683          DOI: 10.2105/ajph.67.7.601

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


× No keyword cloud information.
  4 in total

1.  Evaluation of a screening program for heart disease.

Authors:  G M Matanoski; M M Henderson; O C Stine; C Courpas; R Hepner; S Walker
Journal:  Am J Public Health       Date:  1977-07       Impact factor: 9.308

2.  Screening for disease: Definitions and criteria.

Authors:  L G Whitby
Journal:  Lancet       Date:  1974-10-05       Impact factor: 79.321

3.  Sickle cell "nondisease". A potentially serious public health problem.

Authors:  M L Hampton; J Anderson; B S Lavizzo; A B Bergmen
Journal:  Am J Dis Child       Date:  1974-07

4.  The morbidity of cardiac nondisease in schoolchildren.

Authors:  A B Bergman; S J Stamm
Journal:  N Engl J Med       Date:  1967-05-04       Impact factor: 91.245

  4 in total
  6 in total

1.  How serious are the adverse effects of screening?

Authors:  W Feldman
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

2.  Screening and surveillance of school aged children.

Authors:  J W Tuke
Journal:  BMJ       Date:  1990-05-05

3.  A longitudinal study of military performance subsequent to civilian drug use.

Authors:  J M Rothberg; R J Chloupek
Journal:  Am J Public Health       Date:  1978-08       Impact factor: 9.308

Review 4.  Early identification of alcohol abuse: 1. Critical issues and psychosocial indicators for a composite index.

Authors:  H A Skinner; S Holt; Y Israel
Journal:  Can Med Assoc J       Date:  1981-05-01       Impact factor: 8.262

5.  Comments received on Dr. Bergman's editorial: Pro and Con.

Authors: 
Journal:  Am J Public Health       Date:  1977-12       Impact factor: 9.308

6.  Selling screening.

Authors:  G J Rees
Journal:  J R Soc Med       Date:  1988-02       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.